BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to a series of novel bicyclic derivatives which exhibit in vitro and in vivo inhibition of interleukin-lβ converting enzyme, to compositions containing the novel bicyclic derivatives and to methods for therapeutic utility. More particularly, the interleukin lβ converting enzyme inhibitors described in this invention comprise novel bicyclic derivatives of aldehydes and α-substituted methyl ketones which possess particular utility in the treatment of inflammatory and immune-based diseases of lung, central nervous system, and connective tissues.

Reported Developments

Interleukin lβ (IL-lβ) protease (also known as interleukin-lβ converting enzyme or ICE) is the enzyme responsible for processing of the biologically inactive 31 kD precursor IL-lβ to the biologically active 17 kD form (Kostura, M.J.; Tocci, M.J.; Iimjuco, G.; Chin, J.; Cameron, P.; Hillman, A.G.; Chartrain, N.A.; Schmidt, J.A., Proc. Nat. Acad. Sci., (1989), 86, 5227-5231 and Black, R.A.; Kronheim, S.R.; Sleath, P.R., FEBS Let., (1989), 247, 386-391). In addition to acting as one of the body's early responses to injury and infection, IL-lβ has also been proposed to act as a mediator of a wide variety of diseases, including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, sepsis, acute and chronic myelogenous leukemia and osteoporosis (Dinarello, C.A.; Wolff, S.M., New Engl. T. Med.. (1993), 328_ 106). A naturally occurring IL-lβ receptor antagonist has been used to demonstrate the intermediacy of IL-lβ in a number of human diseases and animal models (Hannum, C.H.; Wilcox, C.J.; Arend, W.P.; Joslin, G.G.; Dripps, D.J.; Heimdal, P.L.; Armes, L.G.; Sommer, A.; Eisenberg, S.P.; Thompson, R.C., Nature. (1990), 343, 336-340; Eisenberg, S.P.; Evans, R.J.; Arend, W.P.; Verderber, E.; Brewer, M.T.; Hannum, C.H.; Thompson, R.C, Nature (1990), 343, 341- 346; Ohlsson, K.; Bjork, P.; Bergenfeldt, M.; Hageman, R.; Thompson, R.C., Nature, (1990), 348, 550-552; Wakabayashi, G., FASEB. (1991), 338-343; Pacifiά, R.; et al. Proc. Natl. Acad. Sci. (1989), §6. 2398-2402 and Yamamoto, L; et al. Cancer Rsh (1989), 49, 4242-4246). The specific role of IL-lβ in inflammation and immunomodulation is supported by the recent observation that the cowpox virus employs an inhibitor of ICE

-1-

SUSSimJI SHEET (S iE 26)

to suppress the inflammatory response of its host (Ray, CA. et al, Cell, (1992), 69, 597- 604).

The importance of these observations is well recognized by those skilled in the art and several workers have proposed and demonstrated in vivo the utility of ICE inhibitors in modifying certain IL-l ^β mediated disease states. Some have suggested the development and therapeutic use of a small molecule inhibitor of mature IL-lβ formation. (See, e.g., Miller, D.K. et al. "The IL-lβ Converting Enzyme as a Therapeutic Target" in Immunosuppressive and Antiinflammatory Drugs; Annals of the New York Academy of Sciences; Vol. 696, ppl33-148, 1993). The following review of the current state of the art in ICE research further supports such utility of ICE inhibitors:

1) WO 9309135, published 11 May 1993, teaches that peptide-based aspartic acid arylacyloxy-and aryloxymethyl ketones are potent inhibitors of ICE in vitro. These compounds also specifically inhibited ICE in the whole cell (in vivo) by their ability to inhibit the formation of mature IL-lβ in whole cells. These ICE inhibitors also demonstrated utility in reducing fever and inflammation/ swelling in rats.

2) Patients with Lyme disease sometimes develop Lyme arthritis. B. burgdorferi, the causative agent of Lyme disease, is a potent inducer of IL-1 synthesis by mononuclear cells. Miller et al. (Miller, L.C.; Lynch, E. A. Isa, S.; Logan, J.W.; Dinarello, C.A.; and Steere, A.C., "Balance of synovial fluid IL-lβ and IL-1 Receptor Antagonist and Recovery from Lyme arthritis", Lancet (1993) 341; 146-148) showed that in patients who recovered quickly from Lyme Arthritis, the balance in synovial fluid of IL-lβ and IL-lra was in favor of IL-ra. When the balance was shifted in favor of IL-lβ, it took significantly longer for the disease to resolve. The conclusion was that the excess IL-lra blocked the effects of the IL-lβ in the patients studied.

3) The IL-1 receptor antagonist, Antril (Synergen), possess significant antiinflammatory activity in patients with active rheumatoid arthritis. In multicenter

Phase II dose ranging study, 175 patients received subcutaneous doses of antril at 20 mg, 70mg and 200mg. The antagonist was found to be most effective when taken daily. After three weeks of daily treatment, patients showed a decrease in joint swelling and less disease activity. A second Phase II clinical trial is scheduled to begin in 1994 (Scrip, NO 1873, 1993). .

-2-

SIIBSΪIΪ SHEET (RiM 26)

4) IL-1 is present in affected tissues in ulcerative colitis in humans. In animal models of the disease, IL-lβ levels correlate with disease severity. In the model, administration of IL-lra reduced tissue necrosis and the number of inflammatory cells in the colon. See, Cominelli, F.; Nast, C.C.; Clark, B.D.; Schindler, R., Llerena, R.; Eysselein, V.E.; Thompson, R.C.; and Dinarello, C.A.; "Interleukin-1 Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis" T. Clin. Investigations (1990) Vol.86, pp, 972-980.

5) The IL-1 receptor antagonist, Antril (Synergen), possess significant antiinflammatory activity in patients with active rheumatoid arthritis. In a multicenter Phase π dose ranging study, 175 patients received subcutaneous doses of Antril at 20mg, 70mg and 200mg seven times, three times or once per week. The antagonist was found to be most effective when taken daily. After three weeks of daily treatment, patients showed a decrease in joint swelling and less disease activity (Scrip, NO 1873, 1993).

6) IL-lra supresses joint swelling in the PG-APS model of arthritis in rats.

See Schwab, J.H.; Anderle, S.K.; Brown, R.R.; Dalldorf, F.G. and Thompson, R.C., "Pro- and Anti-Inflammatory Roles of Interelukin-1 in Recurrence of Bacterial Cell Wall- Induced Arthritis in Rats". Infect. Immun. (1991) 59; 4436-4442.

7) IL-lra shows efficacy in an small open-label human Rheumatoid Arthritis trial. See, Lebsack, M.E.; Paul, C.C.; Bloedow, C.C.; Burch, F.X.; Sack, M.A.; Chase, W., and Catalano, M.A. "Subcutaneous IL-1 Receptor Antagonist in Patients with Rheumatoid Arthritis", Arth. Rheum. (1991) 34; 545.

8) Soluble IL-1 receptor significantly reduces clinically the cutaneous late-phase allergic reaction. This was demostrated in a prospective, randomized, double-blind, placebo-controlled study on 15 allergic subjects. See, Mullarkey, M.F. et al. "Human Cutaneous Allergic Late-Phase Response is Inhibited by Soluble IL-1 Receptor", J. of Immunology, (1994) 152; 2033-2041.

9) IL-1 appears to be an autocrine growth factor for the proliferation of chronic myelogenous leukemia cells. Both IL-lra and sIL-lR inhibit colony growth in cells removed from leukemia patients.

SϋBSTϊϊliTE SHEET (ftl-LE 26>

See, Estrov, Z.; Kurzrock, R.; Wetzler, M.; Kantarjian, H.; Blake, M.; Harris, D.; Gutterman, J.U.; and Talpaz, M., "Supression of Chronic Myelogenous Leukemia Colony Growth by Interleukin-1 (IL-1) Receptor Antagonist and Soluble IL-1 Receptors: a Novel Application for Inhibitors of IL-1 Activity". Blood (1991) 78; 1476-1484.

10) As in 6) above, but for acute myelogenous leukemia rather than chronic myelogenous leukemia.

See, Estrov, Z.; Kurzrock, R.; Estey, E.; Wetzler, M.; Ferrajoli, A.; Harris, D.; Blake, M.; Guttermann, J.U.; and Talpaz, M. "Inhibition of Acute Myelogenous Leukemia Blast Proliferation by Interleukin-1 (IL-1) Receptor Antagonist and Soluble IL-1 Receptors". (1992) Blood 79; 1938-1945.

The IL-1 receptor antagonist, Antril (Synergen), possess significant antiinflammatory activity in patients with active rheumatoid arthritis. In multicenter Phase II dose ranging study, 175 patients received subcutaneous doses of antril at 20 mg, 70mg and 200mg. The antagonist was found to be most effective when taken daily. After three weeks of daily treatment, patients showed a decrease in joint swelling and less disease activity. A second Phase π clinical trial is scheduled to begin in 1994 (Scrip, NO 1873, 1993).

An effective therapy has yet to be fully developed commercially for the treatment of IL-lβ mediated inflammatory diseases. Consequently, there is a need for therapeutic agents effective in the treatment and prevention of these diseases.

SUMMARY OF THE INVENTION

We describe in this invention non-peptide based inhibitors of ICE, specifically where fused bicyclic lactam peptidomimetics serve as recognition elements for ICE. One of the most potent classes of ICE inhibitors described in the literature is the tripeptide i, Z-Val-Ala-Asp-CH2-X (Figure 1: where X = 2,6-dichlorobenzoyloxy; Dolle, R.E. et al, J. Med. Chem. (1994), 3Z, 563) and the related tripeptides described by Thornberry (Thornberry, N.A. et al., Biochemistry (1994), 33, 3934). One well known disadvantage of peptide-based inhibitors is their potential to be extensively metabolized by the body and to be poorly bioavailable when administered orally. By contrast, one significant advantage of peptidomimetic-based inhibitors versus their peptide counterparts is that in vivo metabolism and excretion of such peptidomimetic agents are greatly attenuated, thereby leading to enhanced oral bioavailability of these

-4-

SϋBSr_7UTESϋ£tr( ϋL£26)

compounds in animals and humans (Humphrey, M.J. and Ringrose, P.S., "Peptides and Related Drugs: A Review of Their Absorption, Metabolism, and Excretion", Drug Metabolism Reviews, (1986), -17, 283-310; Plattner, J.J. and Norbeck, D.W. "Obstacles to Drug Development from Peptide Leads", Drug Discovery Technologies. (1990), Chapter 5, 92-126, C.R. Clark and W.H. Moos, eds.; Horwood: Chichester, U.K).

It is for this reason that researchers seek out peptidomimetics to act as surrogates for the peptide portion of pharmacologically active agents. The [7,6]-fused bicyclic lactam present in Structure ii)is such a peptidomimetic for the P3-P2 (Val- Ala) peptide portion of inhibitor i (Structure i). Furthermore, the [7,6]-fused bicyclic system locks the Ψ, ø angles about the amide P3-P2 amide bond in a fixed conformation. Hence, this invention relates to the discovery of a "bio-active" conformation favorable to ICE.

The bicyclic lactam iii (Structures iii-xii) is a rigid system with fixed Ψ, 0 angles. The rigidity of the system has been confimed by X-ray crystallography (Attwodd, M.R.; et al., T. Chem. Soc. Perkin Trans. I (1986), 1011-1019). The Ψ angle has been established to be 163.9°. Logically, by virtue of the rigid bicyclic nature of the fused ring system, any other [7,6]-bicyclic lactam derivative or an analog of iii will have Ψ, 0 angles closely approximating those found in iii and the bioactive conformation needed for high affinity binding to ICE as shown in ii. It is for this reason we state then that any [7,6]- or the related [8,6]-, [7,5]- and [8,5] bicyclic lactam rings and derivatives and analogs thereof, will potentially have the property to act as a substitute for iii. Thus, when they are incorporated into an ICE inhibitor, these peptidomimetics will be active against the enzyme. Examples of lactam rings iv - xii whose synthesis are described in the art and which represent derivatives and analogs of iii are presented in Structures iii-xii.

Furthermore, the stereochemistry about the carbon atoms to which are attached the -NH- and -CO- functional groups as shown in Structures iii-xii should be "S" to acheive maximal potency against ICE. That is to say both the -NH- and -CO- functional groups should be up and on the same face of the bicyclic lactam ring.

SUBSmVfESHEET (BUi£ 26)

Structure i

Peptide-based ICE inhibitor

(Dolle, R.E. et al., J. Med. Chem (1994)

37, 563)

10

Structure ii

Jl

15 [7,6]-Bicyclic lactam-based ICE inhibitor (the invention)

-6-

SUH iϊESHEErpiItt)

Structures iii-xii

The [7,6]-bicyclic lactam peptidomimetic iii and the related bicyclic lactam peptidomimetics iv - xii:

2_ xii

According to the present invention, there is provided a compound of the formula (A) or a pharmaceutically acceptable salt thereof:

Z-N-Y H (A) wherein:

and when R2=OH then Y can also be equal to: wherein

n = 0,1;

R ¹ = H or deuterium;

R ² = OR ⁴ or NHOH;

R ⁴ = H, alkyl, cycloalkyl, aralkyl;

R3 = H, (CR8R9) ₀ _ ₆ CF ₃ , (CR8R9) _(W CF ₂ CF _3/ (CR8R9) ₀ _ ₆ COOR5, (CR8R9) ₀ _ ₆

CONR6R 7, CF ₂ ( C R8R9) ₀ . ₆ aryl, CF ₂ ( C R8R9) ₀ . ₆ heteroaryl, CF ₂ (CR8R9) ₀ _ ₆ alkyl, CHN ₂ ,CH ₂ R ¹⁰ , COR5;

wherein R ⁵ = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl;

SBEET(RϋLE26)

R ⁶ and R ⁷ are independently selected from H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl and where R ⁶ and R ⁷ are taken together can be a 3-,4-,5-,6- or 7-membered carbocyclic ring.

R ⁸ and R ⁹ are independently H, or alkyl;

Rl° = alkyl, aryl, aralkyl, heteroaryl, heteroarakyl, H, halo, SR ⁵ ,

SR5R6, 0(CO)o-iaryl, 0(CO)o-_heteroaryl, OP(0)R"R ^l

R ¹¹ and R ¹² are optionally selected from H, OH, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, aroxy, aralkyloxy, heteroaroxy, heteroaralkyloxy;

R ¹³ = H, alkyl, aryl, aralkyl;

R ¹⁴ and R ¹⁵ are optionally selected from H, alkyl, aryl, or when taken together R ¹⁴ and R ¹⁵ is an aryl ring;

X ¹ = O, S, NR ²⁸ where R ²⁸ = H, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl;

R16.. H, Cl, alkyl, (CR8R9) ₀ _ ₆ -aryl;

-9-

SUBSUME SHEET IE 26)

R ¹⁷ and R ¹⁸ are independently H or alkyl;

X2 = CH ₂ , 0, NR28;

R ¹⁹ = H, alkyl, cycloalkyl, alky ley cloalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl;

R2 ⁰ = H, alkyl, CF ₃ , CF ₂ ,CF ₃ , COOR5, CONR ⁶ R ⁷ , cycloalkyl, alkylcycloalkyl, aryl, aralkyl, heteroaralkyl, heteroaryl and where R ²¹ = H or alkyl;

R22, R23 _/ R24, R25, R26, _an d R2 ⁷ are independently selected from H, alkyl, cycloalkyl, alkylcycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl and R ²⁹ ; and where R ²⁴ and R ²⁵ when taken together may be aryl or heteroaryl;

X ³ = O,S;

R29 = F, Cl, CF ₃ , CF ₂ CF ₃ , (CF ₂ )o-3-H, COOR5, CONR30R31, _w here R30 _a nd R3 are

optionally selected from R ⁶ and R ⁷ ,

wherein

-10-

SUBSm fESH r LE26)

q = 0, l; m = 0,1,2,3; o = 0,1,2;

X = H, alkylthio;

R33 and R34 are optionally H, alkyl, aryl or when taken together, R33 and R 4 are aryl, heteroaryl, or a double bond;

R ³⁵ and R ³⁶ are optionally an oxygen atom or no bond;

R3 = H, alkyl;

R38 = independently selected from H, alkyl, aryl, aralky, heteroaryl, heteroaralkyl, R ⁴ⁿ - SO ₂ , R ⁴¹ -CO, R ⁵⁰ O-CO, R5lNR5-CO;

wherein R ⁴⁰ = R ⁵ or HNR5;

R ⁴¹ = alkenyl, aralkenyl, heteroaralkenyl, alkynyl, aralkynyl, heteroaralkynyl, R ⁴ 2- OCOR ⁵ , R43-COR5, R42-NR47C(=NR6)R5. R42-NR47(=NR6)NR5, R42-SR5, R42-S(CR8R9) ₁ _ ₆ COOR47, R42-S(CR8R9) ₁ _ ₆ COONR47R48, R42_ ₀ R5, R42_ ₀ (CR8R9) ₁ _ ₆

COOR47 R42.0(CR8R9) ₁ ^COONR47R48 _r R42-NR5S02R6, R43-R44, R43.R45, R43.R46, _R 43. NR47 48, R42-OH, R43-CF _3; wherein R42 = (CR8R9) ₁ _ ₇ and R 3 = (CR8 _R 9) _{( 6;}

R44 = H, alkyl, -(CH ₂ )o-4-cycloalkyl;

aryl, heteroaryl, aralkyl, heteroaralkyl, -(CH2)2-6-R ⁹ ; wherein p =1-4;

R49 = alkoxy, CH ₂ F, CHF ₂ , CF ₃ , CF ₂ CF ₃ , OH, COOR47, CONR47R48 , _or NR47R48 .

-11-

SUBSffiUIE SHEET (RI 26)

wherein R ⁴⁸ is independently H, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl,

CH ₂ CH ₂ O-alkyl and C(0)-R49 _;

R ⁴⁷ is independently H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl;

and when R ⁴ and R ⁴⁸ are taken together, they can equal a five, six or seven membered ring of the type:

where p =1 -4 and n= 0-1 ;

R ⁴⁹ is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl;

_R 45 ₌ / \

— N X ¹ and — N ΓΛ

\/ ^£

^R46= ~A \ ^and ^ F _t where p -1-4;

R ⁵⁰ and R ⁵¹ = independently selected from alkyl, R ⁴³ -cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, R ⁴² -alkenyl, R ⁴² -heteroaralkenyl, R ⁴² -alkynyl, R ⁴² -aralkynyl, R ⁴² -heteroaralkynyl, R ⁴ -R ⁴ 6, R42.R49, R52.R45 _/ R42. _C OOR 7, R42-CONR47R48 ₇ R52. OCOR ⁵ , R ⁵² -COR ⁵ , R52-NR ⁴⁷ C(=NR6)R5, R52-NR ⁴ 7(_=NR6)NR5, R52-SR5, R52-S(CR8R9) ₁ _ ₆ COOR ⁴⁷ , R52-S(CR8R9) ₁ ^COONR ⁴ 7R ⁴ 8 _/ R52-OR5, R52_0(C 8R ) ₁ _ ₆

COOR ⁴ , R52-NR5S0 ₂ R ⁶ , R ⁵² -R44, R52. _NR 47R48 _/

where R ⁵² = (CR ⁸ R ⁹ ) ₂ -6;

As used herein, the term "pharmaceutically acceptable salts" include the acid and base addition salts.

The term "acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or

-12-

$t)BSTTϊU7ES T(RULE26)

otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid and the like.

The term "base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaines, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline and caffeine.

As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

"Alkyl" is defined as a saturated aliphatic hydrocarbon which may be either straight- or branched-chain. Preferred groups have no more than about 12 carbon atoms and may be methyl, ethyl, propyl, and so on and structural isomers of propyl, butyl, pentyl, hexyl, octyl, nonyl, decyl, undecyl, dodecyl.

"Cyclolalkyl" is defined as a saturated cyclic aliphatic hydrocarbon containing from at least 3 to as many as 8 carbon atoms. Preferred groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

"Aryl" is defined as a phenyl or naphthyl ring or a substituted phenyl or naphthyl ring wherein one or more of the hydrogen atoms has been replaced by the

-13-

SUBSME SHEET p!I26)

same or different substituents as selected from R43-R5, R43_CN, R ⁴ 3-NO__ R ⁴³ -halo, R ⁴³ - OR ⁵ ,

R ³ -R38, R43- _NR 5 ₀ H, R ³ -CF ₃ , R 3-CF ₂ CF ₃ , R ⁴ 3-COOR ⁵ , R ³ -CONR6R7. R ⁴ 3. CF ₂ (CR ⁸ R ⁹ )o-6heteroaryl, R ⁴ 3-CF ₂ (CR8R9) ₀ . ₆ aryl, R43-CF ₂ (CR8R9) ₀ . ₆ alkyl, R ⁴³ - CON ⁷ R 8, R43.CON30R31, R43-NR5R38, R43. _P ( ₀ )(OH)(OR5). alkenyl, aralkenyl, heteroaralkenyl, alkynyl, aralkynyl, heteroaralkynyl, R43-S02R ⁵ , R ⁴³ -SQ2NR ⁶ R7 _/ R43. NR ⁵ SO ₂ R ⁵³ , R 3-NR ⁵ S0 ₂ R ⁵³ , R ³ -Sθ2-R ⁴² -COOR ⁴ 7. R ⁴ 3-Sθ2-R ⁴² -CONR6R ₇ , R ⁴³ - OCOR ⁵ , R 3-COR ⁵ , R 3-NR ⁴ C(=NR ⁶ )R5, R ⁴ 3-NR ⁴ C(=NR6)R5. R ⁴ 3-S-R ⁴ 3-R5, R43_S- R -COOR47 _. R43-0-R42-COOR47, R43-S-R42-CON 4 R48, R43.0-R43.R5, R43.Q-R52.R45, R43-S-R52-0-R46 _. R43. _S -R52.R45 ₇ R43.S.R46, R43.R45, R43.R46 _{; where} 53 _{= a} lkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroalkyl.

"Heteroaryl" is defined as an unsubstituted or an optionally substituted mono- or bicyclic ring system of about 5 to about 12 carbon atoms and where each monocyclic ring may possess from 0 to about 4 heteroatoms, and each bicyclic ring my possess about 0 to about 5 heteroatoms selected from N, O, and S provided said heteroatoms are not vicinal oxygen and/or sulfur atoms and where the substituents, numbering from 0 to about 5 may be located at any appropriate position of the ring system and are optionally selected from the substituents listed for those described for aryl. Examples of such mono- and bicyclic ring systems which are by no means meant to limit the scope of this invention, including benzofuran, benzothiophene, indole, benzopyrazole, coumarin, isoquinoline, pyrrole, thiophene, furan, thiazole, imidazole, pyrazole, triazole, quinoline, pyrimidine, pyridine, pyridone, pyrazine, pyridazine, isothiazole, isoxazole and tetrazole.

"Aralkyl" refers to an alkyl group substituted by an aryl radical. For example, benzyl.

"Heteroaralkyl" refers to an alkyl group substituted by a heteroaryl radical. For example, (4-pyridyl)methyl.

"Alkoxy" refers to an O-atom substituted by an alkyl radical. For example methoxy, ethoxy, phenoxy, benzyloxy.

"Halo" means iodo, bromo, chloro, and fluoro.

-14-

StlBSffilJTE SHEET (RϋlE 26)

The designation "(CR ⁸ R ⁹ ) ₂ -4" refers to an alkyl linkage composed of at least 2 but not more than 4 carbon atoms where said carbon atoms are independently substituted with radicals described by R ⁸ and R ⁹ . Examples of such linkages include but are not limited to ethyl, propyl, butyl, 2-methylethyl -(MeHCCH ₂ -), and 2,2-dimethylethyl (Me ₂ CCH ₂ -).

"Aroxy" refers to an O-atom substituted by an aryl radical. For example phenoxy.

"Heteroaroxy" refer to an O-atom substituted by a heteroaryl radical. For example pyridinyloxy.

"Alkenyl" refers to an unsaturated hydrocarbon which may be either straight- or branched-chain and have one or more double bonds. Preferred groups have no more than about 12 carbon atoms and may be ethenyl, propenyl, hexadienyl, and so on and structural isomers thereof.

"Alkynyl" refers to an unsaturated hydrocarbon which may be either straight- or branched-chain and have one or more triple bonds. Preferred groups have no more than about 12 carbons atoms and may be ethyl, propynyl, 4-methylpentynl and so on and structure isomers thereof.

"Aralkenyl and heteroaralkenyl" refer to an alkenyl group substituted by an aryl or heteroaryl ring. For example ArCH=CH-, ArCH2C H ₂ C H ₂ HC = C -, CH ₃ CH ₂ CH(Ar)CH ₂ CH ₂ CH=CH-, and so on.

"Aralkynyl and heteroaralkynyl" refer to an alkynyl group substituted by an aryl or heteroaryl ring. For example ArC= C-, ArCH ₂ CH ₂ CH ₂ C= C- and so on.

The present invention also concerns the pharmaceutical composition and method of treatment of IL-lβ protease mediated disease states or disorders in a mammal in need of such treatment comprising the administration of IL-lβ protease inhibitors of formula (I) as the active agent. These disease states and disorders include: infectious diseases, such as meningitis and salpingitis; septic shock, respiratory diseases; inflammatory conditions, such as arthritis, cholangitis, colitis, encephalitis, endocerolitis, hepatitis, pancreatitis and reperfusion injury, immune-based diseass,

-15-

SUBSTITUTE SHEET (EtiJLE 26)

such as hypersensitivity; auto-immune diseases, such as multiple sclerosis; bone diseases; and certain tumors and leukemias.

The present invention has particular utility in the modulation of processing of

-___» IL-lβ for the treatment of rheumatoid arthritis. Levels of IL-lβ are known to be elevated in the synovial fluid of patients with the disease. Additionally, IL-l β stimulates the synthesis of enzymes believed to be involved in inflammation, such as collagenase and PLA2, and produces joint destruction which is very similar to rheumatoid arthritis following intra-articular injection in animals.

10

In the practice of this invention an effective amount of a compound of the invention or a pharmaceutical composition thereof is administered to the subject in need of, or desiring, such treatment. These compounds or compositions may be administered by any of a variety of routes depending upon the specific end use,

15 including orally, parenterally (including subcutaneous, intraarticular, intramuscular and intravenous administration), rectally, buccally (including sublingually), transdermally or intranasally. The most suitable route in any given case will depend upon the use, the particular active ingredient, and the subject involved. The compound or composition may also be administered by means of controlled-release, depot implant

20 or injectable formulations as described more fully herein.

In general, for the uses as described in the instant invention, it is expedient to administer the active ingredient in amounts between about 0.1 and 100 mg/kg body weight, most preferably from about 0.1 to 30 mg/kg body weight for human therapy,

25 the active ingredient will be administered preferably in the range of from about 0.1 to about 20-50 mg/kg/day. This administration may be accomplished by a single administration, by distribution over several applications or by slow release in order to achieve the most effective results. When administered as a single dose, administration will most preferably be in the range of from about 0.1 to mg/kg to about 10 mg/kg.

30

The exact dose and regimen for administration of these compounds and compositions will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment, and the degree of affliction or need. In general, parenteral administration requires lower dosage than other methods of administration

35 which are more dependent upon absorption.

-16-

sωsrπvTE SHEET (RULE 26)

A further aspect of the present invention relates to pharmaceutical compositions comprising as an active ingredient a compound of the present invention in admixture with a pharmaceutically acceptable, non-toxic carrier. As mentioned above, such compositions may be prepared for use for parenteral (subcutaneous, intraarticular, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops or aerosols.

When administered orally (or rectally) the compounds will usually be formulated into a unit dosage form such as a tablet , capsule, suppository or cachet. Such formulations typically include a solid, semi-solid or liquid carrier or diluent. Exemplary diluents and vehicles are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, mineral oil, cocoa butter, oil of theobroma, aginates, tragacanth, gelatin, syrup, methylcellulose, polyoxyethylene sorbitar monolaurate, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, and magnesium stearate.

The compositions may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA, 1985. Formulations for parenteral administration may contain as common excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. Examples of vehicles for parenteral administration include water, aqueous vehicles such as saline, Ringer's solution, dextrose solution, and Hank's solution and nonaqueous vehicles such as fixed oils (such as corn, cottonseed, peanut, and sesame), ethyl oleate, and isopropyl myristate. Sterile saline is a preferred vehicle and the compounds are sufficiently water soluble to be made up as a solution for all foreseeable needs. The vehicle may contain minor amounts of additives such as substances that enhance solubility, isotonicity, and chemical stability, e.g., antioxidants, buffers, and preservatives. For oral administration, the formula can be enhanced by the addition of bile salts and also by the addition of acylcarnitines (Am. T. Physiol. 251:332 (1986)). Formulations for nasal administration may be solid and contain as excipients, for example, lactose or dextran, or may be aqueous or oily solutions for administration in the form of nasal drops or metered spray. For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.

-17-

SUBSTITUTE SHEET (Kt'lf 26)

When formulated for nasal administration the absorption across the nasal mucous membrane is enhanced by surfactant acids, such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, desoxycholic acid, chenodesoxycholic acid, dehydrocholic acid, glycodeoxy-cholic acid, and the like (See, B.H. Vickery, "LHRH and its Analogs-Contraception and Therapeutic Applications", Pt. 2, B.H. Vickery and J.S. Nester, Eds., MTP Press, Lancaster, UK, 1987).

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention were prepared by using the general synthetic methods as described in Schemes 1, 2, 3, 4 and 5. Z-Asparatic add α-bromomethyl ketone (Scheme 1; Formula 1; Z = benzyloxycarbonyl) is treated with an alcohol or a carboxylic acid in the presence of KF using DMF as a solvent to give the α-substituted Z-aspartic acid methyl ketones (Formula 2). The preparation of bromide (Formula 1) and its conversion to compounds of Formula 2 is accomplished using the methods as described by A. Krantz, et al. (Biochemistry, (1991), 30, 4678-4687). Subsequently, the Z- group is removed to generate an N-terminal amine (Formula 3) under hydrogenolytic conditions. The reagents and conditions typically used to carry out the hydrogenolyic removal of the Z-group are hydrogen gas, ambient temperature and pressure, 5% palladium on carbon as the catalyst in an alcoholic solvent e.g., methanol optionally containing two equivalents of hydrochloric acid. It is not necessary to purify the intermediate free amine (or the hydrochloride salt if hydrochloric add is used in the hydrogenolysis), though this material needs to be dry and free of alcohol for the subsequent coupling reaction to proceed in good yield. The amine (Formula 3) so obtained is then condensed with the bicyclic carboxylic acid (Formula 4) to yield intermediates of Formula 5. It is generally necessary to first activate the bicyclic carboxylic acid as an add chloride or mixed anhydride and then react it with the free amine (or hydrochloride salt) in the presence of an organic base, e.g., N- methylmorpholine. Alternatively, coupling the bicyclic carboxylic acid with the intermediate amine is condurted using amide coupling reagents /conditions employed in peptide coupling chemistry ("The Practice of Peptide Synthesis." M. Bodanszky, Springer-Verlag, NY, 1984; The Peptides. Vol 1-3, E. Gross and J. Meienhofer, Eds. Academic Press, NY, 1981). The remaining synthetic transformation to generate the ICE inhibitors is the hydrolysis of the t-butyl ester function. This is conducted by exposing the t-butyl ester (Formula 5) to a 25% solution of trifluoroacetic acid (TFA) in methylene chloride at 25 °C. The de-esterification is usually complete in 3 h. Removal of the volatile TFA and organic solvent affords the aspartic add (Formula 6). The yield of the reaction is quantitative in most instances, providing the t-butyl ester starting material is of high purity. Purification, if required, can be performed by reαystallization or chromatographic techniques which are well known to those skilled in the art. The concentration of TFA may range form 5% - 100% and other organic solvents may be used such as chloroform. Also, a solution of three molar anhydrous hydrochloric add in ethyl acetate may be used in place of the TFA-methylene chloride solution with equal effidency.

-19-

SUBSfiϊ ϊE SHEET (RULE 26)

Scheme 2 outlines the synthesis of the aldehyde containing bicycles. The starting material for their synthesis is the aspartyl semicarbazone (Formula 7). The Z-group is removed via standard hydrogenation conditions to yield the corresponding amine (Formula 8). This is then coupled to the bicyclic carboxylic acid (Formula 4) using coupling conditions analogous to those described above. A double de-protection is required to free the beta carboxylic add (trifluoracetic add) and the alfa aldehyde (37% aqueous formaldehyde, acetic add, methanol) yielding compounds of Formula 10.

Scheme 3 outlines an alternate synthetic method for introdudng R ³⁸ groups onto the bicyclic amino funrtion further enhandng the scope of this invention. Bicydes either as their free acids, esters or aspartic acid amides which contain a Z-group (Formula 11) may be subjected to hydrogenolysis conditions (similar to those described above) to yield the corresponding amino bicycles (Formula 12). The amine moiety may be reacted with add chlorides, activated carboxylic acids (conditions analogous to those used to couple Formula 3 and 4 as described in Scheme 1 above), or sulfonyl chlorides, or isocyanates to afford R ³⁸ containing bicydic lactams with structural diversity in R ³ 8.

The bicyclic lactam of Formula 4 (Scheme 4) was prepared using known methods, see: Attwood; et al., CA100(17):139158j CA, "Bicydic Carboxylic Acids and their Alkyl and Aralkyl Esters", GB 82-13850 820512; and GB 83-5505 830228; Hassall, CH. et al; T. Chem. Soc. Perkin I, 1451-1454, (1979), and Hale, K. J. et al.; Tetrahedron Letters (1992), 33, 7613-7616. The ester was treated with hydrazine under standard conditions (See, Green, T.W.; "Protective Groups in Organic Synthesis"; John Wiley & Sons, 1981) to give the free amine (Formula 15) in high yield. This material was reacted with benzyloxycarbonyl chloride and then TFA also using standard conditions (Formula 15 Formula 16 Formula 4). The details for this series of reactions are given below.

In Scheme 5, the synthesis of other bicyclic lactam derivatives are presented.

Bicyclic lactams of Formulas 17-26 are known in the art. For the synthesis of Formula 17, 18 and 19, see (Hoffmann-La Roche patent); for the synthesis of formula 20, see Flynn, G.A.; et al., I. Amer. Chem. Soc. (1987). 109, 7914-7915; for the synthesis of the compound of formula 21, see Robl, J.A.; et al, T. Amer. Chem. Soc. (1994), 116. 2348- 2355; for the synthesis of compounds of formula 22-24 see, Robl, J.A. Tetrahedron Letters (1994), 35. 393-396; for the synthesis of compounds of formulas 25 and 26, see Wyvratt, M.J. et al. in "Peptides Structure and Function", Proceeding of the Eighth

-20-

SU» .ESϋ!__T(I £2δ)

American Peptide Symposium, Eds. V.J. Hruby and D.H. Rich, pages 551-554, 1983 and Wyvratt, Matthew J., Jr. (Merck and Co., Inc.) S. African ZA 85 07,527 (C1.C07D), 28 May 1986, US Appl. 655818.01 Oct 1984.

By analogy with the chemistry presented in Schemes 1-4, practitioners skilled in the art would readily see that Formulas 17-26 can be transformed into bicyclic lartam inhibitor dasses Formulas 27-36. The phthaloyl protecting group on the amino group can be treated with hydrazine analogous to the Formula 14 15 transformation in

Scheme 4. Indeed such a transformation is reported for Formulas 17-26 in the literature (see previous list of references). This would yield a free amine or its salt which could be treated with PhCH2θCOCl or any reactive group to give R ⁸ - containing inhibitors as in formulas 28-37. As for hydrolysis of the ester fundion in Formulas 17-26, TFA can be used for cases where the esters are t-butyl esters (analogous to Formula 16, Scheme 4). In cases where the ester is an ethyl or methyl ester, aqueous hydroxide anion can be used to effect hydrolysis. After the ester is hydrolyzed to the corresponding acid, the add functionality in turn is used in coupling to the aspartic add derivatives (analogous to Formula 4 5 (Scheme 1) and Formula 4 ► 9 (Scheme 2)) yielding compounds of the type described by Formulas 27-36.

-21-

SU&W E SHEET LE 26)

SCHEME 1

Formula 1 Formula 2

EtOCOCI N-methyl mo holine

Formula 4

Trifluoro- acetic acid

Formula 5 Formula 6

-22-

SUBSϊϊiϋϊϊ SHEET (RULE 26)

SCHEME 2

Formula 7 Formula 8

Formula 4

Formula 9

-23-

SHBSINinESBEE.0iULE._6)

SCHEME 3

Formula 13

SCHEME 4

PhCH ₂ OCOCI

-24-

SUBS iiTESHtEI (ftiJlf 26)

SCHEME 5

The following bicyclic ring systems are known in the literature and by analogy with Schemes 1, 2, 3, and 4, the following classes of compounds can be prepared:

Formula 27

Formula 28

Formula 29

Formula 30

-25-

S BSfffliTE SHEET (RULE 26)

SCHEME 5 (continued)

Formula 31

Formula 32

Formula 34

-26-

SUBSffiϋl - ETTLE 26)

SCHEME 5 (continued)

Formula 35

Formula 36

where

W = OH, OtBu, OMe, OEt, CONH

Z = PI1CH2OCO- (benzyloxycarbonyl); X = 0(CO)o-i aryl, 0(CO)o-i heteroaryl,

-27-

SUKilME SHEET (RULE 26)

where aryl, heteroaryl, X ¹ , X ² , X ³ and R ³⁸ are as previously described.

SYNTHESIS OF INTERMEDIATES OF FORMULAS 16 AND 4

Formula 16

A suspension of (IS, 9S)-t-butyloctahydro-10-oxo-9-phthalimido-6H-pyridazino [l,2-a][l,2]diazepine-l-carboxylate (Formula 14: 4.13 g, 10 mmol) in ethanol (41.3 mL) was treated with hydrazine hydrate (1.1 g, 22 mmol). After the mixture had been stirred for lh at ambient temperature, the solvents were evaporated and the residue azeotroped with toluene. 2M aqueous acetic acid (41.3 mL) was and the mixture stirred for 3 h and then filtered. The filtrate was basified with anhydrous sodium carbonate and 100 mL of dichloromethane was added. Then anhydrous sodium carbonate (1.59 g, 15 mmol) and benzyl chloroformate (2.14 mL, 15 mmol) at room temperature were added and the readion mixture was stirred for 3 h. The organic phase was separated, dried (Na ₂ SO ₄ ) and the product (Formula 16) purified by flash chromatography using 50% ethyl acetate-hexane.

H NMR (300 MHz,CDCl ₃ ) δ 7.4 -7.25 (m, 5H), 5.58 (d, IH), 5.24 (m, IH), 5.08 (s, 2H), 4.7-4.48 (m, 2H), 3.56-3.4 (m, IH), 2.84-2.63 (m, 2H), 2.4-2.3 (m, IH), 2.28-2.20 (m, IH), 1.86-1.44 (m, 4H), 1.41 (s, 9H).

Formula 16

To a stirred solution of t-butyl ester (Formula 16: 3.88 g, 9 mmol) in methylene chloride (30 mL) was added trifluoroacetic acid (50 mL) and stirring continued for 5 h.

-28-

suBsπππEsgEEr(KiiE26)

The solvents were evaporated and azeotroped twice with toluene (30 mL) to give the product (Formula 4) in almost quantitative yield. Mass spectrum: 376 (M+H)

The following further illustrate the compounds of the present invention.

Example 1

r9-(4-Dimethylaminomethyl)benzoylamino)octahydro-6,10-dio xo-6H-pyridazinori,2a1 fl ,2.diazepine-l-formoyπ-L-aspartic add 5-(l-4-chlorophenyl)-3-trifluoromethyl)pyra- zoloxymethyl ketone

Part A: Compound 1 (1.25 g, 3.3 mmol) was dissolved in THF (20 mL). The solution was cooled to -15°C and N-methylmorpholine (440 uL, 4 mmol) was added followed by ethyl chloroformate (342 uL, 3.6 mmol). After stirring for 15 min at -15°C, compound 2 (1.93 g, 4 mmol) was added along with N-methylmorpholine (440 uL, 4 mmol). The readion was stirred 15 min at -15°C and warmed to room temperature over 1 h. Ethyl acetate (200 mL) was added and the solution washed with water (100 mL) and saturated bicarbonate (50 mL) and dried over Na2Sθ ₄ . Chromatography on silica gel

-29-

StlBSirπiTE$HEET(fii&£26)

eluting with a EtOAc-hexane gradient (10-70%) gave 1.5 g (58%) of the coupled produd 3.

Pd Black, H ₂

Part B: Compound 3 (1 g, 1.29 mmol) was dissolved in 200 mL of absolute ethanol. To this was added 6 N HC1 (2.1 mL, 2.58 mmol) and Pd black (100 mg). The solution was reduced on a Paar shaker (30 psi H ₂ ) for 4 h. TLC (70% EtOAc/hexane) showed a R _f drop from 0.75 to 0.00. The Pd was filtered off and solvent evaporated to give a quantative yield of the amine hydrochloride salt 4.

Trifluoroactetic acid

Part C: To 4 (1.18 g, 1.68 mmol) in methylene chloride (40 mL at 0°C) was added 5 (456 mg, 252 mmol). Next, N-methylmorpholine (920 uL, 8.4 mmol) was added along with dimethylaminopyridine (20 mg). The resulting mixture was stirred 30 min at 0°C and lh at 25°C. The reaction mixture was washed with saturated bicarbonate. Purification by silica gel chromatography eluting with a MeOH/ methylene chloride gradient (2- 10% MeOH) gave 1.5 g (76%) of the acylated produd 6. This material was then treated

-30-

SUBSUME SHEET (RULE 26)

with a 25% solution of TFA in CH2CI2 to give the target compound using conditions described for the preparation of Formula 4. Mass spectrum: 776 (M+H).

[9-Benzyloxycarbonylamino)octahydro-6,10-dioxo-6H-pyridaz inoπ.2airi.2ldiazepine- l-formoyll-L-aspartic add aldehyde

1 7 ^β

Part A: In a 200 mL round bottom flask were placed H-Asp(OtBu) semicarbazone 7

(269 mg, 1.17 mmol) diazepine acid 1 (504 mg, 1.35 mmol, 1.1 eq), benzotriazol-1-ly- oxy-tris(dimethylamino)phosphonium Ihexafluorophosphate (BOP) (672 mg, 1.52 mmol, 1.3 eq), HOBT (206 mg, 1.52 mmol, 1.3 eq) along with anhydrous DMF (60 mL).

Then diisopropylethylamine (0.8 mL, 4.68 mmol, 4 eq) was added. The reaction mixture was stirred overnight at 25°C and then the solvent was evaporated in vacuo.

The residue was dissolved in EtOAc and washed with NaHCO ₃ (saturated), H ₂ O (3x), and brine. The organic layer was dried with NaSθ ₄ , filtered and the solvent evaporated to yield white crystals (395 mg, 57%).

Mass spectrum: m/z 558 (M+H).

-31-

SUBSITTUIΪ SHEET (RULE 26)

Part B: In a round bottom flask, 2.0 mmol of 8 was added along with 70 mL of 25% trifluoroacetic acid in dichloromethane. After stirring for 2 h the solvents were removed in vacuo to give a semi-solid residue. The residue was taken up in 30 mL of MeOH to which was added 9 mL each gladal HOAc and of aq. 37% formaldehyde. The mixture was stirred for 2 h and water 50 mL was added. The MeOH was removed in vacuo and the aqueous solution diluted further with water and extracted with EtOAc. Further processing and purification by silica gel chromatography gave aldehyde Example 2 in ca. 50% overall yield from 1. Mass spectrum: m/z 475 (M+H).

Using the methodology as described for the preparation of Example 1 and 2 and referendng Schemes 1, 2 and 3, the following compounds were prepared:

[9-Benzyloxycarbonylamino)odahydro-6.10-dioxo-6H-pyridazi nori.2aiπ,2ldiazepine- l-formoyll-L-aspartic add 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 677 (M+H)

Example 4

r9-Benzyloxycarbonylamino)odahydro-6.10-dioxo-6H-pyridazino� � ,2a1 f 1 ,2 Idiazepine- 1-formoyn-L-aspartic add 5-(l-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone mass spectrum: m/z 715 (M+H)

Example 5

f9-Benzyloxycarbonylamino)odahydro-6,10-dioxo-6H-pyridazi nofl,2a1[1.2ldiazepine- l-formoyl1-L-aspartic add 5-(l-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl ketone mass spectrum: m/z 749 (M+H)

-33-

SUBSUME SHEET (RULE 26)

Example 6

[9-Benzyloxycarbonylamino)odahydro-6.10-dioxo-6H-pyridazinof l,2airi,2]diazepine- l-formoyn-L-aspartic add 5-(l-(2-pyridinyl)-3-trifluoromethyl)pyrazoloxymethyl ketone mass spectrum: m/z 716 (M+H)

Example 7

f9-Benzoylamino)odahydro-6.10-dioxo-6H-pyridazinori,2alfl,2l diazepine-l-formoyn- L-aspartic acid 5-(l-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl ketone mass spectrum: m/z 719= (M+H)

-34-

SUBS iTϋTE SHEET (RULE 26)

f9-(4-Carboxymethylthio)ber_zoylamino)odahydro-6,10-dioxo -6H-pyridazinofl.2al Tl ,2ldiazepine-l-formoyl1-L-aspartic add 5-(l-(4-chlorophenyl)-3-trifluoromethyl)- pyrazoloxymethyl ketone mass spectrum: m/z 809 (M+H)

Example 9

f9-(4-Carboxyethylthio)benzoylamino)odahydro-6.10-dioxo-6 H-pyridazinof 1 ,2a1 Tl .21 diazepine-l-formoyll-L-aspartic add 5-(l-(4-chlorophenyl)-3-trifluoromethyl)pyrazol- oxymethyl ketone mass spectrum: m/z 823 (M+H)

-35-

SUBSΠR!ΪESKΓ IE26)

Example 10

f9-Isobutyloxycarbonylamino)octahydro-6 _> l 0-dioxo-6H-pyridazinoπ ,2a1 Tl ,21 diazepine- l-formoyll-L-aspartic add 5-(l-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl ketone mass spectrum: m/z 715 (M+H)

[9-(4-Dimethylaminomethyl)benzoylamino)octahydro-6,10-dio xo-6H-pyridazinori,2a1 [l,2ldiazepine-l-formoyn-L-aspartic add 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 705 (M+H)

f9-(4-Carboxyethyl)benzoylamino)odahydro-6 _t 10-dioxo-6H-pyridazinori.2a1 ri,2ldiazepine-l-formoyl1-L-aspartic add 5-(l-(4-chlorophenyl)-3-trifluoromethyl)- pyrazoloxymethyl ketone mass spectrum: m/z 791 (M+H)

f9-(4-(N-Morpholinomethyl)benzoylamino)octahydro-6.10-dioxo- 6H-pyridazinofl.2al [l,2ldiazepine-l-formoyn-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 746 (M+H)

-37-

0BsπππεsHEEr(ϋii26)

Example 14

r9-(N-.4-(N-Methylpiperazino)methyl1benzoylamino)octahydr o-6,10-dioxo-6H- pyridazinori,2aiπ,2ldiazepine-l-formoyl1-L-aspartic acid 2.6- dichlorobenzoyloxymethyl ketone mass spectrum: m/z 759 (M+H)

[9-(4-(N-(2-Methyl)imidazolylmethyl ⁾ benzoylamino)odahydro-6,10-dioxo-6H-pyrida- zinofl ,2aiπ ,2ldiazepine-l-formoyl1-L-aspartic add 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 742 (M+H)

-38-

sϋBsπππεsδE r(gui£26)

Example 16

f9-(5-Benzimidazoylamino)octahydro-6,10-dioxo-6H-pyridazi nori,2a1fl,2ldiazepine-l- formoyll-L-aspartic add 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 687 (M+H)

Example 17

f9-(5-Bentriazoylamino)octahydro-6,10-dioxo-6H-pyridazino ri _> 2a1[l,21diazepine-l- formoyll-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 688 (M+H)

-39-

SUKIPI£ BEr i£28)

Example 18

r9-(N-Carboethoxy-5-bentriazoylamino)octahydro-6,10-dioxo -6H-pyridazinoπ.2a1 ri.2ldiazepine-l-formoyπ-L-aspartic add 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 760 (M+H)

Example 19

r9-(N-Carboethoxy-5-benzimidazoylamino)odahydro-6,10-diox o-6H-pyridazino[l,2a1 ri,2ldiazepine-l-formoyl1-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 759 (M+H)

-40-

SUBST i!ESHETPLE26)

r9-(4-Carboxypropyl)benzoylamino)odahydro-6,10-dioxo-6H-p yridazinofl,2a1 [1 ,2ldiazepine-l-formoyl1-L-aspartic acid 5-(l-(4-chlorophenyl)-3-trifluoro- mefhyDpyrazoloxymethyl ketone mass spectrum: m/z 805 (M+H)

Example 21

[9-Benzoylamino)octahydro-6,10-dioxo-6H-pyridazinofl,2a1f l,21diazepine-l-formoyll- L-aspartic acid aldehyde mass spectrum: m/z 446 (M+H) Example 22

-41 -

SU_£π?J!£SJ_E£ϊ(Ri,_ϊ26)

r9-(4-Carboxymethoxy)benzoylamino)octahydro-6,10-dioxo-6H-py ridazinofl,2a1 fl,2ldiazepine-l-formoyl1-L-aspartic add aldehyde mass spectrum: m/z 519 (M+H)

Example 23

r9-Benzyloxycarbonylamino)odahydro-10-oxo-6H-pyridazinori ,2airi,2ldiazepine-l- formoyll-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone mass spectrum: m/z 663 (M+H)

Example 24

[9-Benzyloxycarbonylamino)octahydro-6,10-dioxo-6H-pyridaz ino[l,2aiπ,2ldiazepine- l-formoyl1-L-aspartic acid 5-(l-(4-chloro-2-pyridinyl)-3-trifluoromethyl)pyrazoloxy- methyl ketone mass spectrum: m/z 750 (M+H)

Example 25

r9-(4-Dimethylaminomethyl)benzoylamino)octahydro-6,10-dio xo-6H-pyridazino[l,2a1 [1 ,2ldiazepine-l-formoyl1-L-aspartic acid 5-(l-(2-pyridinyl)-3-trifluoromethyl)pyrazol- oxymethyl ketone mass spectrum: m/z 743 (M+H)

Example 26

f9-(2-Fluorobenzoylamino)octahydro-6,10-dioxo-6H-pyridazi nori,2a1fl,2ldiazepine-l- formoyll-L-aspartic add aldehyde mass spectrum m/z 463 (M+H)

Example 27

r9-(2-Pyridinoylamino)octahydro-6,10-dioxo-6H-pyridazino[ l,2airi,2ldiazepine-l- formoyll-L-aspartic add aldehyde mass spectrum m/z 446 (M+H)

Example 28

f9-(N-r4-Methylpiperazino)methyllbenzoylamino)octahydro-6,10 -dioxo-6H- pyridazinoπ,2a1fl,2ldiazepine-l-formoyl1-L-aspartic acid aldehyde mass spectrum m/z 557 (M+H)

In Vitro Assay

Second order rates of inactivation were obtained by using the enzyme assay described in Dolle, R.E.; et al., T. Med Chem. (1994), 3_7, 563. Note that aldehydes of

Examples 2, 21, 22 and 26-28 are reversible inhibitors and display slow binding kinetics.

In the case of these reversible inhibitors, the in vitro assay was modified to obtain the reversible Ki* as follows:

-44-

SUBSTITUTE SϋΣEΪ (501123)

Ki* values for reversible inhibitors were determined by preincubating ICE with various concentrations of inhibitor in 10 mM HEPES (a common laboratory buffer; pH 7.5), 25% glycerol, 1 mM dithiothreitol for 30 minutes at 37°C in a polystyrene 96-well plate. Remaining ICE activity was measured by adding 10 uM Succinyl-Tyrosine- Valine-Alanine-Aspartic acid-amino methylcoumarin (Bachem Bioscience, Inc.) and monitoring the increase in fluorescence at 37°C using a Fluoroskan π fluorescence plate reader. The Ki* was calculated from a plat of 1/v versus I as described previously (Morrison, J.F. and Cleland, W.W. (1983) Biochemistry 22, 5507-5513.

The compounds of example 1, 3-20, and 23-25 posses IL-lβ protease inhibition

(kobs/[H = >10,000 M'V ¹ ) while compounds of examples 2, 21,22 and 26-28 also possess IL-lβ protease inhibition (Ki* = <10μM).

In Vivo Assay In vivo inhibition (IC5 ₀ ) was determined as follows:

Human monocytes were isolated from heparinized leukopheresis units obtained through Biological Spedalty Corporation (Lansdale, PA). Monocytes were purified by Ficoll-Hupaque (Pharmada Fine Chemicals, Piscataway, NJ) gradient centrifugation and more than 95% pure monocyte populations obtained by centrifugal elutriation. The assay was performed on duplicate samples of freshly isolated human monocytes, cultured in suspension at 37°C and rotated gently in conical bottom polypropylene tubes (Sardstedt Inc., Princeton, NJ). Human monocytes at a concentration of 5 x 10^ cells /mL were resuspended in 1 mL of RPMI 1640 (a common tissue buffer from M.A. Bioproducts, Walkersville, MD) containing 1% fetal calf serum (FCS) (HyClone, Logan, UT) and 50 μg/mL gentamycin (Gibco, Grand Island, NY). The cells were treated either with a compound of the invention (i.e. test compound) or with a non-inhibitor (control compound, typically 0.03% DMSO) for 15 minutes and then adivated with 0.01% fixed Staphylococcus aureus (The Enzyme Center, Maiden, MA) for 1 hour. The cells were then centrifuged and resuspended in 1 mL of cysteine, methionine-free RPMI media containing 1% dialyzed FCS (Hyclone). The cells were pretreated with a test compound or control compound for 15 minutes after which 0.01% fixed S. aureus plus 100 μCi Tran 35-S label (ICN, Irvine, CA) was added and the cells incubated at 37°C for 1 hour. After incubation, cells were centrifuged, washed once in phosphate buffer saline and resuspended in 1 mL RPMI containing 1% fetal calf serum. The cells were again pretreated with a test or control compound for 15 minutes and then 0.01% S. aureus for 2 hours. At the end of the incubation, cells were centrifuged and supernates

saved for immunopredpitation. Cells were washed once in phosphate buffer saline and then lysed in RIP A, a continuous cell media buffer containing 2 mM phenylmethylsulfonyl fluoride, 10 mM iodoacetate, 1 μg/mL pepstatin A, 1 μg/mL leupeptin and 0.5 TIU aprotinin.

For the immunopredpitations, an equal volume of 1% dry milk in RIPA buffer plus 50 μL of resuspended protein A sepharose CL-4B (Pharmacia, Piscataway, New York) was added to supernates and 1 mL of 4% dry milk containing protein A sepharose CL-4B to cell lysates and samples rotated for 30 minutes at 4°C. Beads were then centrifuged down, samples transferred to fresh tubes and incubated overnight with 40 μg rabbit anti-human IL-lβ polyclonal antibody (Genzyme, Cambridge, MA). The IL-lβ proteins were then precipitated with 70 μL protein A sepharose, resuspended in 60 μL SDS sample buffer and run on 15% SGD-PAGE gels. Autoradiography was performed on dried gels and the amount of radioactivity (counts per minute, cpm) quantitated using a Betascope 603 analyzer.

Data Analysis

In the monocyte pulse chase assay, each test parameter was run in duplicate. Data was collected from the Beta Scope using a personal computer, then transferred to the VAX system for calculation of mean cpm and standard deviation of the mean.

When test compounds were evaluated, the percent inhibition of release of mature IL-lβ was calculated as follows:

100 x [1 - (cells treated with stimuli + test compound - unstimulated cells) /(cells treated with stimuli + control compound- unstimulated cells)]

These % inhibition values were then used to calculate IC5 ₀ value for each compound. Since the human monocyte pulse chase assay uses primary cells from different donors, each test compound was run in 2-3 separate experiments, using monocytes from 2-3 different donors.

For examples 1-25, the in vivo IC_o's were <10 μM.

-46-

SUBSK SHETøiiEtt)